Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
about
Overview of current immunotherapeutic strategies for gliomaDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsHMGB1 mediates endogenous TLR2 activation and brain tumor regressionTreg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionHuman Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsEphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelStudy of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyCurrent review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model.Current status of gene therapy for brain tumors.Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Recent developments on immunotherapy for brain cancer.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialHigh-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaFlt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelRecent advances and future of immunotherapy for glioblastoma.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for gliomaGene therapy and virotherapy: novel therapeutic approaches for brain tumors.Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Abundance of Flt3 and its ligand in astrocytic tumorsDevelopment of preclinical models for immunogene therapy of brain cancer: it's not monkey business!Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells.Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren's syndrome.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Current state and future prospects of immunotherapy for glioma.Multifocal low-grade gliomas: Adapting the optimal therapeutic management.Gene therapy and targeted toxins for glioma
P2860
Q26776345-3FED5BBB-A138-41E2-B59B-3EAE0E009637Q27014829-70CB3BE2-E3E4-44E7-9716-4C3FE1CCE1B7Q27307459-42215396-C0DB-4A29-9BAC-D34B75F636BDQ33330270-2B2547C2-ADFE-4F13-9F38-F4D3DFB3EC2FQ33551268-98745222-9C9D-4948-B5E9-5E90FE746384Q33605719-65ABF7EE-7D3B-4A48-970A-9B3E19A756F9Q33740759-8871D8AA-CD53-4678-8E0C-77DB1DA9E690Q33828114-DA37FD81-D446-471B-963C-F3B0A91DCDDAQ33877450-B5B2B89D-08FE-4CD5-AB19-0F3CE9065A98Q33924763-98F2CACC-A61A-4E12-8897-C60852693B35Q34012284-DB3E2D13-4D21-456D-9144-D8BE6B4B33E9Q34022048-7F08830E-7D63-4CD7-A9C0-0B11E9B35590Q34069598-96F08C82-E3A7-49B8-AF91-43BCF5EC755FQ34198939-DBC25642-1E49-4A5D-93D2-22136117E781Q34318157-D903F03F-A34E-4FEB-B725-D08AF575CD26Q34347733-48745742-A329-4906-B309-7F42C4EA5D62Q34647123-74E339BE-A363-47F4-B899-A7478BB44D75Q35285859-5A976004-4D28-476D-B468-A9AC83F507B7Q35527165-B938B277-C880-4F18-8F8A-16577C7AF1A5Q35992355-1738A643-F6FC-4BC5-8AB7-5E27429751CAQ36200438-761AA426-5978-44BF-AEB0-AA1E0708D862Q36534329-043A6E51-5C61-4D4B-86DB-E98F8EF37018Q36540199-747564FE-6488-4372-A944-E03A123F1C1AQ36811505-94079414-1440-4A46-B703-DD6BCA6CC334Q36994063-0AA02CC7-3D3E-433A-8043-A5F05E5F65DFQ37050094-F252AE24-FBE9-4626-BEB0-F18753B9E279Q37239071-973D8BD0-3743-4328-AAB0-26E18A703A52Q37403279-9F252168-FCEB-44FD-B861-BFF2106C20F8Q37730116-A12E08E3-4E8D-4BF1-9A60-0FE5258E1876Q37804933-E825BF5E-D6D8-4F52-B22B-D2D743B0CCA4Q38752688-2F608842-0AA0-4448-BFAB-A037C501A8E1Q41189810-0BCEE0C6-077A-4E6C-97D3-76E641BCA001Q41226132-FD2B785E-924E-4136-BD1D-03DF7DFE8BA3Q41922812-1E703197-BCF9-4121-815F-51254C4F6A11Q42592309-E2595EA7-AFAF-43B6-87A1-ED99DF2D7B10Q44477864-8A6D9D2E-8E42-49AA-9DCF-4ACC480DA0E3Q47318878-88983976-2553-4BC4-90C3-C3822BFADF7BQ50109459-7706FE23-FBF5-4FD4-9364-BE552B2B095BQ55460720-565578CA-8230-4B33-A1AB-23749783FB25Q57006162-2DC80FC9-8690-4EAB-ABB0-9D0FB6A3AE7C
P2860
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
@en
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
@nl
type
label
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
@en
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
@nl
prefLabel
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
@en
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
@nl
P2093
P2860
P50
P1433
P1476
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model
@en
P2093
A K M Ghulam Muhammad
Chunyan Liu
Gwendalyn D King
Mariana Puntel
Marianela Candolfi
Pedro R Lowenstein
Sarah B Honig
Sonali Mondkar
P2860
P356
10.1215/15228517-2007-045
P577
2007-12-13T00:00:00Z